Short Communication - (2025) Volume 16, Issue 1
Glucagon is a crucial hormone involved in glucose metabolism, secreted by the alpha cells of the pancreatic islets of Langerhans. It plays an essential role in maintaining blood glucose levels by promoting glycogenolysis and gluconeogenesis, particularly in fasting states. Its physiological function is counter-regulatory to insulin, preventing hypoglycemia. Beyond its metabolic effects, glucagon has emerging roles in cardiovascular function, lipid metabolism, and gastrointestinal motility. Clinically, glucagon is used in the management of severe hypoglycemia, glucagon stimulation tests, and as an adjunct in imaging studies. Recent advances have also explored its potential in obesity and non-insulin-dependent diabetes mellitus therapies. This article discusses glucagon’s biochemistry, physiological function, clinical applications, and therapeutic potential, emphasizing ongoing research and future directions.
Glucagon, Glucose metabolism, Hypoglycemia, Glycogenolysis, Gluconeogenesis, Diabetes, Pancreatic hormones, Metabolic regulation, Obesity therapy, Endocrine function
Glucagon is a 29-amino-acid peptide hormone primarily secreted by pancreatic alpha cells in response to low blood glucose levels. It plays an essential role in glucose homeostasis by stimulating hepatic glucose production, ensuring adequate energy supply, particularly during fasting or stress. Its action is mediated through the glucagon receptor, a G-protein-coupled receptor found predominantly in the liver. While historically recognized for its role in counteracting insulin-induced hypoglycemia, glucagon’s broader physiological effects have gained increasing attention. Beyond its metabolic function, glucagon influences lipid metabolism, cardiovascular dynamics, and gastrointestinal motility. In recent years, its potential therapeutic applications in metabolic disorders such as obesity and type 2 diabetes have been extensively studied. Understanding glucagon’s mechanisms and applications can provide insight into novel treatment strategies for metabolic diseases [1, 2].
Glucagon synthesis occurs within the pancreatic alpha cells, where it is initially produced as proglucagon and subsequently processed into active glucagon by prohormone convertase enzymes. The primary stimulus for glucagon secretion is hypoglycemia, but other factors, such as amino acids and sympathetic nervous system activation, can also enhance its release. The liver serves as the main target organ for glucagon, where it promotes glycogen breakdown (glycogenolysis) and the formation of glucose from non-carbohydrate sources (gluconeogenesis). These processes help restore blood glucose levels, ensuring homeostasis. In addition to its hepatic effects, glucagon exerts physiological actions on adipose tissue, promoting lipolysis, which contributes to energy availability. It also has a mild inotropic effect on the heart and plays a role in gastrointestinal motility by relaxing smooth muscles, making it useful in imaging studies such as radiological examinations of the stomach and intestines. Furthermore, glucagon influences appetite regulation by interacting with the central nervous system, suggesting a role in weight management interventions [3, 4].
Clinical studies have established the efficacy of glucagon in various applications, particularly in the management of hypoglycemia. Glucagon administration in emergency settings effectively raises blood glucose levels in patients experiencing severe insulin-induced hypoglycemia. Furthermore, glucagon stimulation tests are widely used for assessing endocrine disorders, including adrenal insufficiency and growth hormone deficiencies. Research has also demonstrated glucagon’s role in lipid metabolism, with studies suggesting its potential in reducing hepatic steatosis and improving lipid oxidation. Additionally, recent investigations into dual and tri-agonist therapies, which combine glucagon receptor activation with other metabolic pathways, have shown promise in obesity and type 2 diabetes treatment by enhancing energy expenditure and glucose control [5].
While glucagon has well-established roles in glucose metabolism and clinical applications, ongoing research continues to uncover new dimensions of its function. One area of interest is the development of glucagon-based therapeutics for obesity management. Dual agonists targeting glucagon and glucagon-like peptide-1 (GLP-1) receptors have been shown to improve weight loss and glycemic control more effectively than GLP-1 agonists alone. Another potential application involves the modulation of glucagon signaling to treat nonalcoholic fatty liver disease (NAFLD) by enhancing lipid oxidation and reducing hepatic triglyceride accumulation. Despite its benefits, glucagon therapy faces certain limitations. The hormone’s short half-life necessitates frequent administration or the use of modified formulations to prolong its action. Additionally, excessive glucagon activity is implicated in the pathogenesis of type 2 diabetes, where hyperglucagonemia contributes to persistent hyperglycemia. Targeting glucagon’s effects in a controlled manner remains a critical challenge in designing therapeutic interventions. Further research is needed to optimize glucagon-based treatments while minimizing adverse metabolic consequences [6-8].
Glucagon is an essential hormone that plays a pivotal role in glucose homeostasis, lipid metabolism, and gastrointestinal function. Its clinical applications extend beyond hypoglycemia management to include diagnostic testing and emerging therapeutic strategies for metabolic disorders. Advances in glucagon-based therapies, particularly in obesity and type 2 diabetes, highlight its expanding medical significance. However, challenges related to its pharmacokinetics and metabolic effects warrant further investigation. Continued research into glucagon’s physiological roles and therapeutic potential holds promise for improving metabolic disease management and expanding treatment options for patients worldwide.
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Received: 01-Jan-2025, Manuscript No. jdm-25-36978; Editor assigned: 03-Jan-2025, Pre QC No. jdm-25-36978(PQ); Reviewed: 17-Jan-2025, QC No. jdm-25-36978; Revised: 22-Jan-2025, Manuscript No. jdm-25-36978(R); Published: 29-Jan-2025
Copyright: © 2025 Habtom DT. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
